Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$37.97 - $50.0 $1.25 Million - $1.65 Million
-32,909 Reduced 72.0%
12,800 $575,000
Q4 2022

Feb 14, 2023

SELL
$41.06 - $66.48 $2.61 Million - $4.22 Million
-63,526 Reduced 58.16%
45,709 $2 Million
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $4.92 Million - $7.66 Million
98,522 Added 919.65%
109,235 $7.2 Million
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $484,548 - $751,516
10,713 New
10,713 $541,000
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $2.08 Million - $3.56 Million
-43,318 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$66.73 - $82.59 $5.01 Million - $6.2 Million
-75,052 Reduced 63.4%
43,318 $3.47 Million
Q3 2019

Nov 14, 2019

SELL
$72.9 - $101.41 $7.16 Million - $9.95 Million
-98,156 Reduced 45.33%
118,370 $8.7 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $8.7 Million - $11.6 Million
118,313 Added 120.47%
216,526 $20.4 Million
Q1 2019

May 15, 2019

SELL
$48.7 - $86.6 $5.44 Million - $9.67 Million
-111,653 Reduced 53.2%
98,213 $7.86 Million
Q4 2018

Feb 14, 2019

BUY
$45.57 - $74.26 $4.38 Million - $7.13 Million
96,007 Added 84.32%
209,866 $11.3 Million
Q3 2018

Nov 14, 2018

BUY
$58.91 - $78.32 $6.71 Million - $8.92 Million
113,859 New
113,859 $8.89 Million
Q2 2018

Aug 14, 2018

SELL
$60.96 - $101.18 $4.6 Million - $7.64 Million
-75,488 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$73.28 - $102.95 $1.85 Million - $2.6 Million
25,278 Added 50.34%
75,488 $6.92 Million
Q4 2017

Feb 14, 2018

SELL
$62.91 - $88.32 $3.8 Million - $5.34 Million
-60,483 Reduced 54.64%
50,210 $3.79 Million
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $4.69 Million - $7.71 Million
110,693
110,693 $7.71 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.